| Elevate Uranium Ltd (EL8) ORDINARY FULLY PAID |
Energy |
$114 |
Proposed issue of securities - EL8
|
23 Dec 2025 9:53AM |
$0.270 |
$0.245 |
fallen by
9.26%
|
|
| Chimeric Therapeutics Limited (CHM) ORDINARY FULLY PAID |
Health Care |
$4 |
$8.4 M funding to drive CHM CDH17 and resignation of CMO
|
23 Dec 2025 9:53AM |
$0.003 |
$0.067 |
risen by
2,133.33%
|
|
CHM - Price-sensitive ASX Announcement
Full Release
Key Points
- $8.4 million total funding through placement and convertible note.
- Funding fully supports CHM CDH17 CAR-T trial to the end of Phase 1.
- Strategic review underway to streamline costs and align operations.
- Resignation of Chief Medical Officer Dr. Jason B. Litten during restructuring.
- Commitments from US-based investors with shareholder approval pending.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vintage Energy Ltd (VEN) ORDINARY FULLY PAID |
Energy |
$5 |
Amended target dates for Southern Flank gas interest
|
23 Dec 2025 9:53AM |
$0.004 |
$0.002 |
fallen by
50%
|
|
| Metgasco Limited (MEL) ORDINARY FULLY PAID |
Energy |
$1 |
VEN: Amended target dates for Southern Flank gas interest
|
23 Dec 2025 9:53AM |
$0.026 |
$0.014 |
fallen by
46.15%
|
|
| Vintage Energy Ltd (VEN) ORDINARY FULLY PAID |
Energy |
$5 |
MEL: Sale Agreement with Vintage - Updated Timetable
|
23 Dec 2025 9:53AM |
$0.004 |
$0.002 |
fallen by
50%
|
|
VEN - Price-sensitive ASX Announcement
Full Release
Key Points
- Metgasco Ltd extends the commitment deadline for Vintage Energy by one month to 31 January 2026.
- The completion date for the transaction remains unchanged at 31 March 2026.
- Metgasco's Extraordinary General Meeting is scheduled for 14 January 2026.
- The transaction involves the sale of a 25% interest in the Odin and Vali Gas Fields.
- The agreement is part of Metgasco's strategy to divest its non-operated interests.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Metgasco Limited (MEL) ORDINARY FULLY PAID |
Energy |
$1 |
Sale Agreement with Vintage - Updated Timetable
|
23 Dec 2025 9:53AM |
$0.026 |
$0.014 |
fallen by
46.15%
|
|
MEL - Price-sensitive ASX Announcement
Full Release
Key Points
- Metgasco Ltd ASX code MEL.
- Sale agreement with Vintage Energy Ltd for 25% interest in Odin and Vali Gas Fields.
- Target date for commitment extended to 31 January 2026.
- Completion deadline remains 31 March 2026.
- Extraordinary General Meeting on 14 January 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| KKR Credit Income Fund (KKC) ORDINARY UNITS FULLY PAID |
Financials |
$652 |
Dividend/Distribution - KKC
|
23 Dec 2025 9:52AM |
$2.280 |
$2.020 |
fallen by
11.40%
|
|
| Carnegie Clean Energy Limited (CCE) ORDINARY FULLY PAID |
Utilities |
$57 |
2025 Basque Tax Deductions Sold
|
23 Dec 2025 9:52AM |
$0.065 |
$0.140 |
risen by
115.38%
|
|
CCE - Price-sensitive ASX Announcement
Full Release
Key Points
- Carnegie Clean Energy Limited, through its subsidiary Carnegie Technologies Spain, has sold its 2025 Basque R&D tax deductions for €773,163.
- The eligible R&D expenditure involved procurement of CETO components and was approved under the Basque Country's tax incentive mechanism.
- The ACHIEVE Programme was recognized for R&D purposes, allowing tax deductions creation and transfer.
- All funds from the tax deductions sale are expected to be received by 31 December 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neurizon Therapeutics Limited (NUZ) ORDINARY FULLY PAID |
Health Care |
$47 |
Notice under s708AA(2)(f)
|
23 Dec 2025 9:51AM |
$0.110 |
$0.061 |
fallen by
44.55%
|
|
| Neurizon Therapeutics Limited (NUZ) ORDINARY FULLY PAID |
Health Care |
$47 |
Proposed issue of securities - NUZ
|
23 Dec 2025 9:51AM |
$0.110 |
$0.061 |
fallen by
44.55%
|
|
| Neurizon Therapeutics Limited (NUZ) ORDINARY FULLY PAID |
Health Care |
$47 |
Proposed issue of securities - NUZ
|
23 Dec 2025 9:50AM |
$0.110 |
$0.061 |
fallen by
44.55%
|
|
| Neurizon Therapeutics Limited (NUZ) ORDINARY FULLY PAID |
Health Care |
$47 |
Equity Raising Presentation
|
23 Dec 2025 9:50AM |
$0.110 |
$0.061 |
fallen by
44.55%
|
|
NUZ - Price-sensitive ASX Announcement
Full Release
Key Points
- Equity raising to fund HEALEY ALS Platform Trial.
- Placement of new shares and entitlement offer initiated.
- Convertible Note Facility provides additional funding flexibility.
- Global license agreement with Elanco secured for NUZ-001.
- Focus on cost reduction and accelerated trial timelines.
- Outline of operational milestones and potential risks.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neurizon Therapeutics Limited (NUZ) ORDINARY FULLY PAID |
Health Care |
$47 |
New Funding Secured for HEALEY ALS Platform Trial
|
23 Dec 2025 9:49AM |
$0.110 |
$0.061 |
fallen by
44.55%
|
|
NUZ - Price-sensitive ASX Announcement
Full Release
Key Points
- Neurizon secured ~$7.1 million from shareholders and investors.
- A $20 million convertible note facility established with Obsidian Global GP, LLC.
- Funding supports participation in HEALEY ALS Platform Trial for NUZ-001.
- Trial aims to treat ALS, the most common form of motor neuron disease.
- Funding combines share placements and strategic financing.
- Participation in the trial starts early Q1 CY2026.
- Trial includes a randomised clinical trial and active treatment extension phases.
- Neurizon aims to explore broader applications for NUZ-001.
- Funding structure minimizes dilution and aligns with clinical milestones.
- The trial is pivotal for future regulatory and commercial initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Core Lithium Ltd (CXO) ORDINARY FULLY PAID |
Materials |
$963 |
EL8:Acquisition of Napperby Uranium Resource
|
23 Dec 2025 9:48AM |
$0.270 |
$0.298 |
risen by
10.19%
|
|
| Elevate Uranium Ltd (EL8) ORDINARY FULLY PAID |
Energy |
$114 |
Acquisition of Napperby Uranium Resource
|
23 Dec 2025 9:48AM |
$0.270 |
$0.245 |
fallen by
9.26%
|
|
EL8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Elevate Uranium Ltd has finalized the acquisition of Uranium Generation Pty Ltd from Core Lithium Ltd.
- The acquisition includes the Napperby Uranium Project in the Northern Territory and additional uranium projects in South Australia.
- The Napperby Project contains a JORC 2012 compliant Mineral Resource of 8.03 Mlb at 382 ppm U3O8.
- The acquisition increases Elevate Uranium's global Mineral Resource inventory to 169 Mlb U3O8.
- The strategy involves applying the U-pgradeâ„¢ process to enhance value from the acquired assets.
- Additional tenements in NT and SA are expected to provide exploration potential.
- A net smelter royalty of 1.0% on production from Napperby is part of the acquisition agreement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MRG Metals Limited (MRQ) ORDINARY FULLY PAID |
Materials |
$12 |
Proposed issue of securities - MRQ
|
23 Dec 2025 9:46AM |
$0.004 |
$0.004 |
fallen by
0%
|
|
| MRG Metals Limited (MRQ) ORDINARY FULLY PAID |
Materials |
$12 |
Placement to Advance REE and HMS Projects
|
23 Dec 2025 9:45AM |
$0.004 |
$0.004 |
fallen by
0%
|
|
| MRG Metals Limited (MRQ) ORDINARY FULLY PAID |
Materials |
$12 |
MRG Acquires High Grade REE Garies Project in South Africa
|
23 Dec 2025 9:44AM |
$0.004 |
$0.004 |
fallen by
0%
|
|
MRQ - Price-sensitive ASX Announcement
Full Release
Key Points
- MRG Metals Limited has acquired the high-grade Garies Rare Earth Elements (REE) Project in South Africa.
- The Garies Project is located close to the Steenkampskraal Monazite Mine, one of the world's highest-grade rare earth projects.
- The project includes a high-value heavy rare earth component, with approximately 9% heavy rare earth oxides (HREO).
- Monazite grades are up to 8%, supporting high-value concentrate pricing.
- The project may support rapid development of a small-scale mine after obtaining a mining license.
- The company plans to use cash flows from its Mozambique Heavy Mineral Sands joint venture to minimize shareholder dilution.
- The Garies Project has a large 275 km² exploration footprint, with 190 km² applied for and awaiting approval.
- Bulk sampling has shown grades up to 4.85% Total Rare Earth Oxides (TREO).
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Echelon Resources Limited (ECH) ORDINARY FULLY PAID |
Energy |
$78 |
Change of Director's Interest Notice
|
23 Dec 2025 9:43AM |
$0.335 |
$0.350 |
risen by
4.48%
|
|
| Scorpion Minerals Limited (SCN) ORDINARY FULLY PAID |
Materials |
$14 |
OZZ :Binding Option Agreement Executed
|
23 Dec 2025 9:42AM |
$0.025 |
$0.025 |
fallen by
0%
|
|
| Ozz Resources Limited (OZZ) ORDINARY FULLY PAID |
Materials |
$7 |
Binding Option Agreement Executed
|
23 Dec 2025 9:42AM |
$0.055 |
$0.055 |
fallen by
0%
|
|
| Sprintex Limited (SIX) ORDINARY FULLY PAID |
Consumer Discretionary |
$46 |
Trading Halt
|
23 Dec 2025 9:41AM |
$0.060 |
$0.066 |
risen by
10%
|
|
SIX - Price-sensitive ASX Announcement
Full Release
Key Points
- Sprintex Limited requested a trading halt for its securities.
- The halt is pending an announcement about a material purchase order.
- Trading halt is effective from 23 December 2025.
- The halt will last until 29 December 2025 or until an announcement is made.
- The request was authorized by the board of directors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BCI Minerals Limited (BCI) ORDINARY FULLY PAID |
Materials |
$1,087 |
Primary Approvals Received for Optimised Dredge Strategy
|
23 Dec 2025 9:40AM |
$0.385 |
$0.370 |
fallen by
3.90%
|
|
BCI - Price-sensitive ASX Announcement
Full Release
Key Points
- BCI Minerals secures primary governmental approvals for optimised dredge strategy.
- Approvals provided under both Commonwealth and Western Australian environmental laws.
- Dredging program to support the Mardie Salt Operation at Cape Preston West Port.
- Dredging expected to start in April 2026, with first salt shipment by December 2026.
- The approvals enhance project scheduling and budget management, mitigating risks.
- The initiative positions BCI as a significant player in the global industrial salt market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kairos Minerals Limited (KAI) ORDINARY FULLY PAID |
Materials |
- |
More Outstanding Drill Hits at Mt York
|
23 Dec 2025 9:38AM |
$0.033 |
$0.710 |
risen by
2,051.52%
|
|
KAI - Price-sensitive ASX Announcement
Full Release
Key Points
- Kairos Minerals Limited (ASX:KAI) announced more outstanding drill results at Mt York.
- Drill results include significant intercepts such as 51m at 2.42 g/t Au from 54m at Main Hill.
- Results from 12 additional holes at Main Hill and Breccia Hill prospects were reported.
- The 2025 drilling campaign at Mt York was completed with 26,971 meters drilled.
- Kairos expects these results to positively impact the Mt York Mineral Resource Estimate (MRE) in Q1 2026.
- The company has a cash balance of $30.4M following recent fundraising.
- Geologists reported sulphide-bearing BIF at the Mt York Extension.
- The drilling program used historic PLS reconnaissance data for drill hole positioning.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Invion Limited (IVX) ORDINARY FULLY PAID |
Health Care |
$4 |
Hanlim & Korean Government Fund Pathway to Clinical Trial
|
23 Dec 2025 9:37AM |
$0.081 |
$0.041 |
fallen by
49.38%
|
|
IVX - Price-sensitive ASX Announcement
Full Release
Key Points
- Non-dilutive funding secured from Hanlim Pharm and KDDF.
- Two-stage development program worth up to A$2 million.
- Stage 1: Efficacy studies in oesophageal cancer animal models.
- Stage 2: Preparation for human trials in Australia.
- Significant market opportunity due to unmet needs in oesophageal cancer.
- Partnership aims to advance Photosoft technology for cancer treatment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.